What Cotareg Treats: Main Uses and Benefits

Cotareg is a fixed-dose medication primarily used in the treatment of hypertension (high blood pressure). The medication is applied across conditions characterized by periods of heightened symptoms, such as high blood pressure. The combination is often used when supportive symptom management is appropriate to help with symptomatic fluctuations associated with a single agent, or in clinical settings that involve acute or unstable symptom patterns.

The overall benefit in managing these symptoms related to heightened physiological activity is highly relevant, as lowering blood pressure contributes to easing the systemic burden associated with the risks of cardiovascular events. The combination is commonly used to help with symptoms related to physiological strain and systemic imbalance, providing support that helps ease the overall symptom burden. This medication is relevant when supportive symptom management is appropriate to help maintain functional stability.

The dual action may assist with effective blood pressure control, which contributes to easing the overall symptom load associated with sustained hypertension.

Quick Fact: Relief for Symptoms related to heightened physiological activity

Regulatory References

1. NIH DailyMed Official Label for Valsartan/HCTZ

Cotareg is a combination medication containing valsartan and hydrochlorothiazide (HCTZ), and it is typically prescribed to treat high blood pressure (hypertension).

Who Can Use Cotareg

Cotareg is generally safe and effective for adults whose blood pressure is not adequately controlled by either valsartan or HCTZ alone. It may also be used as initial therapy in patients who are likely to need multiple medications to achieve their blood pressure goals, as determined by a healthcare provider. Use is always dependent on a full medical history and assessment of individual risk factors.

---

Who Should Not Use Cotareg (Contraindications)

Certain conditions and patient groups prevent the use of Cotareg due to increased risk of serious side effects. These include:

Patient Group or Condition	Reason for Contraindication
Allergy/Hypersensitivity	Known allergy to valsartan, HCTZ (or other sulfonamide-derived drugs), or any excipients in Cotareg.
Pregnancy	Can cause serious injury or death to the developing fetus, especially during the second and third trimesters.
Anuria	Patients who are unable to produce urine (severe kidney impairment).
Aliskiren Use	Contraindicated in patients with diabetes or moderate-to-severe kidney impairment who are also taking aliskiren.

Note: This is not an exhaustive list. Patients should always disclose all medical conditions and medications to their healthcare provider before starting Cotareg.

Interactions with other medicines and products

The interaction profile of Cotareg, a fixed-dose combination of Valsartan and Hydrochlorothiazide (HCTZ), is formally documented by regulatory authorities and centers on managing pharmacodynamic reinforcement and exposure alterations.

Contraindicated and Restricted Combinations

Co-administration with Aliskiren is contraindicated in patients with diabetes or moderate-to-severe renal impairment (GFR le 60 mL/min/1.73 m^2). This restriction prevents dual blockade of the Renin-Angiotensin-Aldosterone System (RAAS).

Pharmacokinetic and Pharmacodynamic Interactions

• Exposure Alteration: Agents that inhibit the OATP1B1/1B3 uptake transporters (e.g., Rifampin, Cyclosporine) or efflux transporters (e.g., Ritonavir) may increase the systemic exposure (AUC) of Valsartan.
• Additive Effects: Co-administration with Potassium-sparing diuretics or Potassium supplements carries a risk of hyperkalemia. Combining with other antihypertensive agents or substances like alcohol can potentiate orthostatic hypotension.
• Clearance Interference: Concomitant use with Lithium results in increased serum Lithium concentrations and a risk of toxicity due to reduced clearance.
• NSAIDs: Combining with Non-Steroidal Anti-Inflammatory Drugs may lead to a reduced blood pressure lowering effect and an increased risk of renal function deterioration.

Administration Timing Rule

To ensure proper absorption of HCTZ, co-administration with ion exchange resins (e.g., Cholestyramine or Colestipol) requires staggering the dosage. The Hydrochlorothiazide component must be administered at least 4 hours before or 4 to 6 hours after the administration of the resin.

Cotareg is a fixed-dose combination of Valsartan (an Angiotensin II Receptor Blocker, ARB) and Amlodipine (a Dihydropyridine Calcium Channel Blocker, CCB).

Valsartan non-competitively and selectively blocks the binding of angiotensin II to the angiotensin II type 1 (AT1) receptor on vascular smooth muscle and the adrenal gland. This receptor blockade inhibits the vasoconstrictive effects of angiotensin II and reduces aldosterone secretion. The resulting mechanistic cascade decreases peripheral vascular resistance.

Amlodipine acts by inhibiting the transmembrane influx of calcium ions into vascular smooth muscle cells and, to a lesser extent, cardiac muscle. This inhibition of calcium entry prevents muscle cell contraction, primarily producing peripheral arterial vasodilation and decreasing total peripheral resistance.

This dual mechanism achieves a combined effect on vascular tone by modulating the Renin-Angiotensin-Aldosterone System (RAAS) and direct smooth muscle excitation, consequently decreasing ventricular afterload and myocardial wall tension.

How to Use Cotareg: Official Administration Guidelines

Cotareg (Valsartan/Hydrochlorothiazide) is a fixed-dose combination medication intended for oral administration only. The official instructions for its use focus on a standardized, sustained regimen for systemic blood pressure management.

---

Dosing and Schedule

Administration Principle	Official Guideline
Dosing Frequency	The tablet is taken once daily.
Standard Regimen	A typical starting dose when transitioning from single-agent therapy is 160 mg / 12.5 mg (Valsartan/HCTZ) once daily.
Maximum Dose	The highest dose specified is 320 mg / 25 mg once daily.
Dose Adjustment	Dose changes, if necessary, are generally considered only after 1 to 2 weeks of therapy to allow the full effect of the previous dose to manifest.

---

Intake and Contextual Conditions

The tablet can be taken with or without food. It is required to swallow the film-coated tablet whole with fluid (such as water). If a dose is missed, it should be taken as soon as remembered, unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped entirely; double doses must not be taken.

In some cases, the combination product is not recommended as initial treatment, particularly for patients who may be volume depleted. The full therapeutic effect is typically observed within 4 weeks, though this may extend up to eight weeks.

---

Population-Specific Usage Thresholds

No initial dose adjustment is required for older adults. For patients with mild to moderate renal impairment, no dose adjustment is necessary. However, for those with mild to moderate hepatic impairment without cholestasis, the valsartan dose should not exceed 80 mg, which restricts the use of certain higher-strength combinations. The combination is generally not recommended for use in children and adolescents under 18 years of age.

Research Evidence / Overview of Studies for Cotareg

Evidence for use in Essential Hypertension

Research on Cotareg (valsartan/hydrochlorothiazide) for high blood pressure includes short-term Randomized Controlled Trials (RCTs). These studies were used in research examining outcomes related to blood pressure changes in adults with essential hypertension. The researchers compared the combination against an inactive placebo, against the two individual components (valsartan or hydrochlorothiazide alone), and against other specific active comparator treatments.

Comparison Studies: Cotareg Versus Other Treatments

This section outlines research that examined Cotareg against specific active comparator treatments. The trials monitored outcomes related to systemic or functional imbalance, such as blood pressure measurements, to describe the measured changes under the specific conditions of the study. Findings indicate patterns related to blood pressure changes when Cotareg was studied alongside its individual components, where research explored patterns in measured outcomes across the compared groups. It is important to note that comparative evidence is lacking for long-term outcomes, such as how the combination compares to other specific treatments regarding major health events.

Long-Term Follow-up and Durability of Response

Research has explored whether the measured physiological patterns relating to blood pressure are sustained over defined time intervals. This area was studied in research examining longer observation periods, including patients observed over several months rather than short periods. However, long-term effects are not fully established regarding sustained clinical outcomes related to major health events. The key limitation is that follow-up durations were limited in many of the core efficacy studies.

What is Still Uncertain About Cotareg Studies

Evidence contributes to the broader understanding of this combination therapy, noting what has been studied and what remains uncertain. The primary limitation is the focus of the available research on surrogate outcomes monitoring physiological strain or stress (blood pressure readings), rather than direct long-term outcomes related to major health events. Data are still emerging for certain populations, and certainty remains low for long-term clinical outcomes due to the typically short duration of the primary efficacy trials.

Key Studies & References Clinical Guideline on the Management of Arterial Hypertension (e.g., ACC/AHA or ESC guidelines) Referenced for Therapeutic Context

Common questions about Cotareg (FAQ)

---

Q: Can I get a generic version of Co-Tareg?

Yes, Cotareg is available as a generic combination product containing the active ingredients valsartan and hydrochlorothiazide. Official regulatory information confirms that generic versions of this fixed-dose combination are approved and listed.

---

Q: Does this drug cause sun sensitivity?

Official product information notes that the hydrochlorothiazide component may make your skin more sensitive to the sun and ultraviolet (UV) light. It is also associated with an increased risk of non-melanoma skin cancer with long-term use. Official product information suggests minimizing sun exposure while using this medication.

---

Q: Will this medicine affect my blood sugar?

Official labeling states that the hydrochlorothiazide component may cause an increase in blood sugar levels, a condition known as hyperglycemia. For individuals with diabetes, this could potentially require a change in the dosage of other antidiabetic medicines.

---

Q: Can I drink alcohol while taking this?

According to official regulatory documents, consuming alcohol while taking this medication can increase the effects of the blood pressure-lowering components. Official documents indicate this can increase the potential risk of developing dizziness, light-headedness, or fainting (orthostatic hypotension).

---

Q: Can I take this if I have swelling in my legs (edema)?

Official safety documents indicate that swelling of the feet, ankles, or hands (peripheral edema) has been reported as an adverse reaction in clinical studies for this medication.

---

Q: What are the signs of a serious allergic reaction?

Official safety information lists Angioedema as a serious adverse reaction. This involves swelling of the face, lips, throat, and/or tongue which may cause difficulty breathing or swallowing. Regulatory guidance states that if this type of swelling occurs, the medication should be discontinued.

---

Q: Can I take this with my cholesterol medication?

The hydrochlorothiazide component may cause increases in certain blood lipid levels, such as cholesterol and triglycerides. Additionally, official documents note that certain cholesterol-lowering agents, like ion exchange resins (e.g., cholestyramine), can interfere with the absorption of the hydrochlorothiazide component.

---

Q: Does this drug cause sleep problems?

Regulatory documents list insomnia (difficulty sleeping) as a reported adverse reaction observed in clinical trials for this medication. This effect is part of the officially documented safety profile.

---

Q: Is it safe to drive while taking this?

Official product information advises caution regarding activities requiring mental alertness. Because this medication can cause dizziness or lightheadedness, official product information cautions against driving or operating machinery until it is known how the medication affects an individual.

---

Q: Is this medication safe for long-term use?

The medication is officially indicated for the long-term management of high blood pressure. However, the hydrochlorothiazide component is associated with an increased risk of non-melanoma skin cancer with prolonged use, a factor described in official safety warnings.

How to Store and Dispose of Cotareg?

Cotareg film-coated tablets must be stored at Controlled Room Temperature, which is 25 C (77 F), with allowed temperature fluctuations between 15 C and 30 C. To maintain stability, the medication must be protected from moisture and kept in the original container or a tightly closed container.

Handling and Safety

The product must not be stored above 30 C and should be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Cotareg must be disposed of according to local requirements. The medication should not be thrown into household waste or flushed down the toilet.